Merck eye drug matches anti-VEGF in DME trial with safety caveats

Merck (MRK) reported one-year results from its BRUNELLO trial for remigromig, an investigational drug for diabetic macular edema (DME). Both doses met the primary endpoint, showing non-inferiority to ranibizumab in visual acuity improvement. However, adverse events related to proliferative diabetic retinopathy were more frequent with remigromig. Merck plans to discuss results with regulators and is conducting further analyses.

Original reporting
Published Oct 10, 2026, 10:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 10:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$MRK
Neutral
high confidence
Mentioned
$MRK
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MRKNeutralMed
01

Why it matters

The non‑inferior efficacy positions remigromig as a possible alternative to anti‑VEGF therapy, but safety signals may temper enthusiasm.

02

Market read

First disclosure of pivotal trial results for a major pharma player; could affect MRK stock and ophthalmology biotech sector.

03

What to watch

Potential for regulatory scrutiny over higher PDR rates and need for longer‑term data.

Relevance 8/10Novelty 8/10Timing: same-day release

Background

Merck presented the data at the American Academy of Ophthalmology meeting, highlighting its novel tri‑specific antibody.

Company-level read

Ticker impact

$MRKNeutralHigh confidence
Context

Merck reported Phase 2b/3 BRUNELLO trial data showing remigromig met primary endpoint with non‑inferior visual acuity gains versus ranibizumab.

Expected impact

potential modest pressure as investors weigh safety concerns against efficacy

Evidence & confidence

First‑time disclosure of pivotal trial results; efficacy is positive but safety signals may limit upside.

Market effects

May influence other ophthalmology biotech peers as a Wnt‑pathway approach gains data.

Limited to US biotech and pharma markets.

Modest, primarily affecting investors tracking ophthalmology drug pipelines.

Counterpoint

Safety concerns could outweigh efficacy, prompting a sell‑off if adverse events rise.

Key entities

  • Merck

    Pharmaceutical company conducting the trial.

  • remigromig

    Investigational tri‑specific antibody targeting the Wnt pathway.

Related articles

$SLSHighAI 8/10

SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too

BlackRock and a Vanguard unit added SLS, IBRX, IOVA, MRK, and LLY to their Q3 buy lists. Lilly reported strong sales from diabetes, obesity, and cancer drugs. Sellas (SLS) awaits Phase 3 trial results for its AML treatment. ImmunityBio (IBRX) plans expanded FDA approval for Anktiva. Iovance (IOVA) saw 77% YoY sales growth for Amtagvi and is testing it with Merck's (MRK) Keytruda. Retail sentiment varies across stocks.

$MRKMedAI 9/10

He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment

Merck (MRK) and Moderna (MRNA) reported a Phase 3 trial where a personalized vaccine, combined with Keytruda, kept 82.2% of melanoma patients cancer-free for two years, compared to 70.0% with Keytruda alone. The vaccine is not yet FDA-approved, so Medicare does not cover it outside of clinical trials. Patients may face out-of-pocket costs for trial participation.

$MRKMedAI 8/10

AHA 2026: Pharmacists at the Center of Cardiometabolic Care

At AHA 2026, data on new cardiometabolic therapies highlighted pharmacists' growing role. Survodutide (Zealand Pharma, Boehringer Ingelheim) showed cardiovascular safety. Enlicitide (Merck) sustained LDL-C reductions. Stanford's model embedded pharmacists in heart failure care. Orforglipron (Eli Lilly) lowered systolic blood pressure. Pharmacists were noted for their critical roles in titration, adherence, and monitoring.

$MRKHigh

Merck announces European CHMP recommends approval of Enflonsia

Merck (MRK) announced the European CHMP recommended approving an expanded indication for Enflonsia to prevent RSV in high-risk children up to 24 months. The European Commission will review this recommendation, with a decision expected in two months. Enflonsia was previously approved by the FDA and EU for RSV prevention in infants. The CHMP opinion is based on Phase 3 trial results.